Mapping the evidence: from epidemiology to mechanism
The idea that tea drinking is good for the heart is at once ancient and intensely modern. In traditional Chinese medicine, teas were classified by their thermal nature and presumed influence on qi and blood, but the notion of a measurable effect on the vessels and the pump belongs entirely to the laboratory. The first wave of epidemiological studies, starting in the 1990s, compared populations with high tea intake — notably in Fujian, Guangdong, and Zhejiang — to those with lower consumption, finding inverse associations with stroke and coronary heart disease. But these were observational hints, not proof.
Things changed with the publication of comprehensive meta-analyses, including the much-cited Cardiovascular meta-analyses 2024 — what the latest review found, which pooled data from over 800,000 participants and focused specifically on Chinese tea types — green, oolong, black, and pu-erh. That review confirmed a J-shaped dose-response curve: a reduction in cardiovascular mortality at 2–4 cups per day, with diminishing returns and potential risk at very high intake. The effect was most pronounced for green and lightly oxidised oolong teas, likely because of their high catechin content.
Meanwhile, mechanistic studies have zeroed in on endothelial function. The endothelial lining of blood vessels reacts to oxidative stress and inflammation, and tea polyphenols, especially epigallocatechin-3-gallate (EGCG), appear to improve flow-mediated dilation within hours of ingestion. A randomised controlled trial from 2018, conducted at a hospital in Shanghai, showed that a single dose of Longjing green tea improved brachial artery dilation in healthy adults more than a caffeine-matched control, suggesting that the effect is polyphenol-driven rather than simply a caffeine kick. This line of inquiry is detailed in Green tea and blood pressure — the daily-intake studies.
Lipid panels have also drawn attention. Oolong tea and the lipid panel — the Anxi cohort study tracked more than 2,000 residents of Anxi county, the oolong heartland, over five years. Habitual drinkers of Tieguanyin and other traditional oolongs saw a modest but consistent reduction in LDL cholesterol and triglycerides relative to non-drinkers, with the effect strengthening after three years. The Anxi data are particularly valuable because they come from a population with a stable, well-characterised tea ritual, minimising recall bias — something that plagues many tea-health studies conducted in Western populations where tea habits are notoriously inconsistent.
Still, the literature has its gaps. Hard endpoints — myocardial infarction, heart failure hospitalisation — remain understudied in randomised trials for Chinese teas specifically. And there is the perennial problem of confounding: tea drinkers in China also tend to have higher incomes, lower smoking rates, and better access to healthcare. The 2024 meta-analysis tried to parse these confounders, but residual uncertainty lingers. The research community is also beginning to ask whether the processing method matters — does the microbial fermentation of pu-erh add a lipid-lowering dimension beyond the catechins? Early animal work is promising, but human data are sparse.
For the curious reader, tea.doctor maintains a running bibliography, including the three articles referenced here, alongside links to full-text publications where available. You can also explore related topics on thetea.app, our sister site that catalogues the teas themselves with detailed origin and brewing notes, or tea.school, which offers deeper dives into tea chemistry for students and professionals. The story of tea and cardiovascular health is still being written — but the chapters completed so far are compelling enough to warrant a second cup.